Spruce Biosciences has patented a method for treating Congenital adrenal hyperplasia (CAH) using a novel pharmaceutical composition. The method involves administering a CRF1 receptor antagonist along with reduced doses of glucocorticoids to lower hormone levels in patients. GlobalData’s report on Spruce Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Spruce Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Spruce Biosciences's grant share as of May 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of congenital adrenal hyperplasia (cah) using crf1 receptor antagonist
A recently granted patent (Publication Number: US12005065B2) discloses a method for treating congenital adrenal hyperplasia (CAH) in humans. The method involves administering a CRF1 receptor antagonist or a pharmaceutically acceptable salt, along with a reduced second dose of glucocorticoid compared to the first dose. The CRF1 receptor antagonist is administered at a dose between 50 mg/day and 200 mg/day, leading to a reduction in androstenedione (A4), adrenocorticotropic hormone (ACTH), or 17-hydroxyprogesterone (17-OHP) levels in the subject from baseline. The antagonist is stable for storage for at least six months, ensuring its efficacy over time.
Furthermore, the method specifies that the reduction in A4, ACTH, or 17-OHP levels should be at least 5% from baseline, with variations up to 25% also considered effective. The administration of the first dose of glucocorticoid should be closely timed with the CRF1 receptor antagonist intake, and the glucocorticoid can be selected from a range of options like hydrocortisone. The patent also details the stability range of the CRF1 receptor antagonist between 25°C and 40°C, allowing for convenient storage and use. Overall, this method presents a novel approach to treating CAH by combining specific dosages of a CRF1 receptor antagonist and glucocorticoid to achieve desired hormonal level reductions in affected individuals.
To know more about GlobalData’s detailed insights on Spruce Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
